Literature DB >> 12351404

Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells.

Ikuya Sakai1, Kazuto Takeuchi, Hayato Yamauchi, Hirosi Narumi, Shigeru Fujita.   

Abstract

Because suppressor of cytokine signaling (SOCS) proteins are negative regulators of cytokine-induced signaling, it has been hypothesized that aberrant SOCS expression confers resistance against cytokine therapy. This study reports on the constitutive expression of SOCS3 in most chronic myelogenous leukemia (CML) cell lines, which are resistant to treatment with interferon alpha (IFN-alpha). In contrast, the KT-1/A3 cell line, in which constitutive expression of SOCS3 is barely detectable, is sensitive to IFN-alpha treatment. Forced expression of SOCS3 in the KT-1/A3 cell line confers resistance to IFN-alpha treatment. Furthermore, most of the blast cells from patients in CML blast crisis, which are usually resistant to IFN-alpha therapy, showed constitutive expression of SOCS3. These findings indicate that constitutive SOCS3 expression affects the IFN-alpha sensitivity of CML cell lines and blast cells from patients with CML blast crisis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351404     DOI: 10.1182/blood-2002-01-0073

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

Review 1.  Suppressors of cytokine signaling in health and disease.

Authors:  Jane C Tan; Ralph Rabkin
Journal:  Pediatr Nephrol       Date:  2005-02-19       Impact factor: 3.714

Review 2.  Negative regulation of cytokine signaling.

Authors:  Akihiko Yoshimura
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

3.  Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients.

Authors:  Guanghua Li; Jianbo Xu; Zhao Wang; Yujie Yuan; Yin Li; Shirong Cai; Yulong He
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-28       Impact factor: 4.553

4.  Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.

Authors:  Dongjun Lee; Ying-Hua Wang; Demetrios Kalaitzidis; Janani Ramachandran; Homare Eda; David B Sykes; Noopur Raje; David T Scadden
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

5.  Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells.

Authors:  Kazuya Matsumoto; Jun-ichi Okano; Yoshikazu Murawaki
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

6.  Oncogenic Ras inhibits IRF1 to promote viral oncolysis.

Authors:  Y Komatsu; S L Christian; N Ho; T Pongnopparat; M Licursi; K Hirasawa
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

7.  Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.

Authors:  Efstratios Katsoulidis; Antonella Sassano; Beata Majchrzak-Kita; Nathalie Carayol; Patrick Yoon; Alison Jordan; Brian J Druker; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

8.  Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.

Authors:  Gregory B Lesinski; Jason M Zimmerer; Melanie Kreiner; John Trefry; Matthew A Bill; Gregory S Young; Brian Becknell; William E Carson
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

Review 9.  SOCS regulation of the JAK/STAT signalling pathway.

Authors:  Ben A Croker; Hiu Kiu; Sandra E Nicholson
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

10.  Long-term pegylated interferon-alpha and its potential in the treatment of melanoma.

Authors:  Reinhard Dummer; Joanna Mangana
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.